The Association of the British Pharmaceutical Industry has launched a public consultation exercise on its Code of Practice, to coincide with a series of amendments that are required to be implemented by July 1. Any interested parties are invited to respond to the review. Heather Simmonds, the director of the Prescription Medicines Code of Practice Authority, said: "the Code and its operation are regularly revised every two or three years and suggestions for revisions are always welcome."
One of the reasons for the current revision is a new policy on the funding of, and cooperation with, patient groups, which was announced by the European Federation of Pharmaceutical Industries and Associations (EFPIA; Marketletter November 26), of which the ABPI is a member.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
ABPI invites comment on UK Code of Practice
The Association of the British Pharmaceutical Industry has launched a public consultation exercise on its Code of Practice, to coincide with a series of amendments that are required to be implemented by July 1. Any interested parties are invited to respond to the review. Heather Simmonds, the director of the Prescription Medicines Code of Practice Authority, said: "the Code and its operation are regularly revised every two or three years and suggestions for revisions are always welcome."
One of the reasons for the current revision is a new policy on the funding of, and cooperation with, patient groups, which was announced by the European Federation of Pharmaceutical Industries and Associations (EFPIA; Marketletter November 26), of which the ABPI is a member.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze